Dostarlimab plus niraparib for advanced penile cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether combining dostarlimab (an immunotherapy) with niraparib (a cancer pill) can shrink advanced penile cancer and keep it from growing. It may help people whose cancer has progressed after limited prior treatments, and who have not had certain immune therapies before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III (unresectable) or stage IV penile cancer that doctors confirmed with a tissue test.
- Your cancer must have measurable disease on scans (doctors can measure it).
- You should be able to do normal activities with limited help (ECOG 0–1, sometimes 2 by special approval).
- You have not had more than one prior treatment line in the locally advanced setting or after platinum chemotherapy.
- You cannot have used prior immune checkpoint treatments (like anti–PD-1/PD-L1/CTLA-4), cancer vaccines, or similar immune-targeting therapies.
- You must be well enough for treatment: adequate organ test results and prior chemo side effects are mostly resolved (except hair loss and mild nerve symptoms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
This trial studies whether blocking PD-1 (an immune “brake”) along with niraparib (a DNA-repair blocker) can shrink or control recurrent/progressive uterine carcinosarcoma after prior chemotherapy. It’s for people whose cancer has grown again and who meet specific health and lab requirements.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
Hear when a new Penile Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.